Evidence map›Paper›PMID 42287316›Full record

ReviewNaunyn-Schmiedeberg's archives of pharmacology2026

Kaempferol: advances in biosynthesis, molecular mechanisms, and therapeutic applications.

Eman S Zaki, Miral O Sabry, Fatma I Abou-Elazm, Ahmed M El-Dessouki, Samar S Khalaf, Asmaa Ramadan, Riham A El-Shiekh, Amany S Aboutaleb

Abstract readReview
PubMed Publisher
In one paragraph

Review in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Eman S ZakiPharmacology and Toxicology Department, Faculty of Pharmacy, Heliopolis University, Cairo, Egypt.
Miral O SabrySingapore Institute of Manufacturing Technology (SIMTech), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
Fatma I Abou-ElazmDepartment of Microbiology and Immunology, College of Pharmaceutical Sciences and Drug Manufacturing, Misr University for Science and Technology, 6th of October City, Egypt.
Ahmed M El-DessoukiPharmacology and Toxicology Department, Faculty of Pharmacy, Ahram Canadian University, 6th of October City, Giza, 12566, Egypt.
Samar S KhalafBiochemistry Department Faculty of Pharmacy Heliopolis University, Cairo, Egypt.
Asmaa RamadanDepartment of Biochemistry, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa City, Egypt.
Riham A El-ShiekhDepartment of Pharmacognosy, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo, 11562, Egypt. riham.adel@pharma.cu.edu.eg.ORCID http://orcid.org/0000-0002-3179-3352
Amany S AboutalebPharmacology and Toxicology Department, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo, 11754, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Kaempferol is a ubiquitous dietary flavonol found in fruits, vegetables, and medicinal plants, existing in both aglycone and glycosylated forms which contribute to its structural and functional diversity. This review provides a comprehensive overview of kaempferol, focusing on its biosynthesis, pharmacokinetic challenges, and the mechanistic basis for its diverse pharmacological properties. Its biosynthesis originates from phenylalanine, with subsequent enzymatic modifications yielding derivatives of varying bioactivity. The principal mechanism of kaempferol is rooted in its potent antioxidant capacity, acting through both direct radical scavenging and the upregulation of the cytoprotective Nrf2 pathway. This redox modulation is intricately linked to its anti-inflammatory effects, which are mediated by the suppression of key signaling cascades including NF-κB, MAPKs, and STATs. In preclinical models, kaempferol demonstrates significant antidiabetic activity by activating AMPK and enhancing insulin sensitivity. Its anticancer properties are equally notable, involving the induction of apoptosis, cell cycle arrest, and inhibition of metastasis through the disruption of pathways such as PI3K/AKT and Wnt/β-catenin. Furthermore, it exhibits antimicrobial effects and hepatoprotective actions by modulating SIRT1/AMPK signaling. Despite these promising bioactivities, therapeutic translation is severely hampered by its poor aqueous solubility and extensive first-pass metabolism, which critically limit oral bioavailability. Consequently, while kaempferol is a compelling polypharmacological agent with the potential to address complex diseases, its unfavorable pharmacokinetic profile remains the critical bottleneck for clinical advancement. A promising direction for future research is to prioritize the development of advanced drug delivery systems and the execution of rigorous clinical trials to translate its extensive preclinical promise into validated clinical applications.

Indexed as

AntioxidantsKaempferolsAnimalsHumansHypoglycemic AgentsSignal TransductionAntioxidantsHypoglycemic AgentskaempferolKaempferolsBiological activitiesDerivativesDrug discoveryKaempferol

Identifiers

PMID42287316

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.